Not a real image of the product.
  • ScreenPro (SCRN) obtains a digital COVID-19 passport company
  • ScreenPro and GoStop will enter into a definitive share purchase agreement
  • Users will be able to have alerts either on a daily, weekly or monthly basis
  • This platform can be used not only for ScreenPro’s current COVID testing but also for vaccine scheduling
  • ScreenPro (SCRN) is up 5.00 per cent and is trading at C$0.10 at 12:45 pm EST

Compel Capital Inc., or ScreenPro Security (SCRN), has entered a binding letter of intent to acquire 100 per cent of GoStop Inc.

GoStop Inc is a private COVID-19 digital passport medical services company, incorporated under British Columbia laws.

Subject to the completion of satisfactory mutual due diligence within 30 days by ScreenPro and GoStop and under the LOI terms and conditions, ScreenPro and GoStop will enter into a definitive share purchase agreement.

This purchase agreement will acquire 100 per cent of the issued and outstanding common shares of GoStop.

John McMullen, the CEO, stated, “This acquisition is an accretive move for our company. To have a digital health passport that maintains key personal medical statistics on the patient not only enables the clearance for the user to enter to workspace.”

“We believe that to offer and implement this strategy to our current client base, our company has the potential to generate an additional revenue stream to our current testing business strategy,” concluded McMullen.

GoStop is a digital COVID-19 passport developed using a privacy-preserving approach using decentralized proximity tracing that will enable people to use the alerting software and downloadable app for infections through the track and tracing by utilizing patient device authentications certificates.

Post due diligence and upon final closing, ScreenPro plans to integrate this application into ScreenPro’s current reporting system, making it more patient-centric.

Users will receive alerts on-demand: on a daily, weekly or monthly basis.

This platform can be used not only for ScreenPro’s current COVID testing, but also be used for vaccine scheduling.

ScreenPro provides turnkey coronavirus screening solutions to the private sector.

ScreenPro’s unique access to multiple manufacturers of high-quality South Korean test kits and its strategic partnership with Canvas Labs in Vancouver and Integrated Explorations in Ontario.

ScreenPro (SCRN) is up 5.00 per cent and is trading at C$0.10 at 12:45 pm EST.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

How a small-cap tech stock is broadening MRI technology 

Nanalysis Scientific (TSXV:NSCI) develops and makes compact MRI and nuclear magnetic resonance devices for clinical, lab and industrial use.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.